Market Overview

The Global Anti-Obesity Drugs Market was valued at USD 2,767.5 million in 2023 and is expected to reach USD 9,520.5 million by 2031 while growing at a CAGR of 16.7% during the forecast period (2024-2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global anti-obesity drugs market growth. The perfect anti-obesity medication would induce prolonged weight reduction while causing minimal side effects. However, the mechanisms governing energy balance possess significant redundancy, overlap extensively with other physiological processes, and are impacted by social, hedonic, and psychological factors, thereby constraining the efficacy of pharmacological interventions.

The market experiences growth propelled by increasing obesity rates, health awareness campaigns, and government initiatives and policies. Nonetheless, safety concerns and limited efficacy pose hindrances to its expansion.

Furthermore, the global anti-obesity drugs industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Mechanism of Action Analysis

The Global Anti-Obesity Drugs Market is segmented among Peripherally Acting Anti-Obesity Drugs, and Centrally Acting Anti-Obesity Drugs, based on Mechanism of Action. In 2023, Peripherally Acting Anti-Obesity Drugs accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Type Analysis

The Global Anti-Obesity Drugs Market is segmented among Prescription Drugs, and OTC Drugs, based on Type. In 2023, Prescription Drugs accounted for the majority of the market share*.

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Anti-Obesity Drugs Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).

*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Anti-Obesity Drugs Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Anti-Obesity Drugs Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Anti-Obesity Drugs Market Segmentation, By Mechanism of Action

• Global Anti-Obesity Drugs Market Share Analysis, By Mechanism of Action

• Global Anti-Obesity Drugs Market Growth Analysis, By Mechanism of Action

• Global Anti-Obesity Drugs Market Trends, By Mechanism of Action

o Peripherally Acting Anti-Obesity Drugs

o Centrally Acting Anti-Obesity Drugs,

6. Global Anti-Obesity Drugs Market Segmentation, By Type

• Global Anti-Obesity Drugs Market Share Analysis, By Type

• Global Anti-Obesity Drugs Market Growth Analysis, By Type

• Global Anti-Obesity Drugs Market Trends, By Type

o Prescription Drugs

o OTC Drugs

7. Global Anti-Obesity Drugs Market Segmentation, By Region

• Global Anti-Obesity Drugs Market Share Analysis, By Region

• Global Anti-Obesity Drugs Market Growth Analysis, By Region

• Global Anti-Obesity Drugs Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

8. Competitive Landscape

• VIVUS Inc.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Pfizer Inc.

• Novo Nordisk

• Bayer AG

• F Hoffmann-La Roche

• Glaxosmithkline

• Arena Pharmaceuticals

• Eisai Co. Ltd.

• Takeda Pharmaceutical Company

• Nalpropion Pharmaceuticals Inc

*Similar analysis will be provided for each company listed above.